**Name of Journal:** ***World Journal of Hepatology***

**Manuscript NO: 37044**

**Manuscript Type: Meta-Analysis**

**Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data**

Saberi B *et al*. Vitamin D does not predict the stage of hepatic fibrosis in NAFLD

**Behnam Saberi, Alia S Dadabhai, Julie Nanavati, Lin Wang, Russell T Shinohara, Gerard E Mullin**

**Behnam Saberi, Alia S Dadabhai, Gerard E Mullin,** Division of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States

**Behnam Saber,** Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

**Julie Nanavati,** Welch Medical Library, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States

**Lin Wang,** Department of Epidemiology, Johns Hopkins-Bloomberg School of Public Health, Baltimore, MD 21205, United States

**Russell T Shinohara,** Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States

**ORCID number:** Behnam Saberi (0000-0002-7157-5827); Alia S Dadabhai (0000-0001-8367-6396); Julie Nanavati (0000-0002-8356-0278); Lin Wang (0000-0003-1338-2100); Russell T Shinohara (0000-0001-8627-8203); Gerard E Mullin (0000-0001-5317-6788).

**Author contributions:** Saberi B, Dadabhai AS and Mullin GE contributed to the data evaluation, manuscript and figure preparation, editing and final submission; Shinohara RT and Wang L provided biostatistics methodology oversight, as well as data extractions, meta-analysis with pooled data figure preparation and manuscript preparation and editing; Nanavati J provided informatics methodology support, conducted the literature search, and reviewed and edited the manuscript.

**Conflict-of-interest statement:** None.

**Data sharing statement:** The authors of the following studies were contacted to obtain their approval to share data in order to systematically evaluate their data for our meta-analysis: Dr. Patel, Luger, Barchetta, Anty, Bril, and Targher.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Gerard E Mullin, MD,** **Associate Professor,** Department of Gastroenterology and Hepatology, The Johns Hopkins Hospital, 600 N Wolfe Street, Carnegie 464B, Baltimore, MD 21287, United States. gmullin1@jhmi.edu

**Telephone:** +1-410-5024270

**Fax:** +1-410-5024478

**Received:** November 7, 2017

**Peer-review started:** November 8, 2017

**First decision:** December 4, 2017

**Revised:** December 12, 2017

**Accepted:** January 15, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate the relationship between 25-hydroxyvitamin D [25(OH)D] levels and fibrosis stage in patients with non-alcoholic fatty liver disease (NAFLD).

***METHODS***

Two individual reviewers identified relevant studiesusing the PubMed, EMBASE, Cochrane, and Scopus databases. Inclusion criteria were as follows: (1) Studies that evaluated adults with NAFLD and serum or plasma 25(OH)D levels; and (2) assessed fibrosis stage using liver biopsy. A rigorous analysis yielded six articles as having sufficient data to employ in evaluating the association of serum vitamin D levels in patients with NAFLD based on their liver fibrosis stage by histopathological analysis. The lead investigators of each of the six studies were contacted and the data were collected. To meta-analyze vitamin D levels in F0-F2 *vs* F3-F4 fibrosis, a random-effects meta-analysis fit using restricted maximum likelihood was applied. To examine trends across each stage of fibrosis with respect to vitamin D levels, a meta-regression was performed. *P* < 0.05 was considered statistically significant.

***RESULTS***

Total of 937 subjects from six studies were included in the final analysis to evaluate the association of serum vitamin D levels in patients with NAFLD based on their liver fibrosis stage by histopathological analysis. The lead investigators of each of the six studies were contacted and the data were collected. First, the investigators performed a meta-analysis to compare serum vitamin D levels in patients with NAFLD with stage F0-F2 compared to F3-F4, which did not show significance [meta-estimate of the pooled mean difference = -0.86, *P* = 0.08 (-4.17, 2.46)]. A meta-regression evaluation of serum vitamin 25 (OH)D levels across the individual stages (F0-F4) of fibrosis did not show an association for the six included studies.

***CONCLUSION***

Low vitamin D status is not associated with higher stages of liver fibrosis in patients with NAFLD.

**Key words:** Vitamin D; 25-hydroxyvitamin D; Liver fibrosis; Meta-analysis; Nonalcoholic fatty liver disease; Non-alcoholic steatohepatitis

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Non-alcoholic fatty liver disease (NAFLD) is a condition that can progress to cirrhosis, hepatic failure, and liver cancer. Vitamin D sufficiency is impaired in the advanced stages of liver disease and in NAFLD. However, our systematic review of the literature and meta-regression confirms that the serum 25-hydroxyvitamin D levels in patients with NAFLD are not associated with the severity of hepatic fibrosis.

Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. *World J Hepatol* 2018; In press

**INTRODUCTION**

Non-Alcoholic fatty liver disease (NAFLD) represents a growing epidemic that requires better understanding in order to develop new therapeutic targets[1]. The definition of NAFLD is based upon the presence of ≥ 5% hepatic steatosis without having etiologies, such as alcohol[2]. As one of the most prevalent causes of liver disease worldwide, the importance of NAFLD is gaining prominence in the medical literature and in the press. The prevalence of NAFLD is estimated to be 6% to 35% worldwide and 10% to 35% in the United States, increasing parallel to diabetes and obesity[3-5]. Based on these studies, it is estimated that between 75 million to 100 million individuals are at-risk of having NAFLD in the United States. NAFLD is a condition which has a range of manifestations from steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma[1]. The number of adults with NASH on the liver transplant list has grown by a factor of three, and NASH is the 2nd most common etiology of liver disease in patients who are awaiting liver transplantation[6].

Vitamin D is well known for its physiologic role in mineral and skeletal homeostasis[7]. Ultraviolet light from sun exposure transforms 7-dehydrocholesterol, into pre-vitamin D3, which is converted into vitamin D3 (cholecalciferol). Vitamin D controls the expression of genes linked to various processes including immunomodulation which may be highly pertinent to chronic liver disease. Vitamin D has numerous properties that modulate injury, tissue remodeling, fibrogenesis, and chronic inflammation, which may prevent the progression of chronic liver disease[8,9]. Vitamin D has immunomodulatory actions that include the attenuation of interleukin-2, interferon-γ, and interleukin-12, which drive pro-inflammatory T-helper-1 (Th1) response (Figure 1)[10]. Vitamin D upregulates anti-inflammatory T-helper-2 (Th2) cytokines and induces regulatory T cells (Tregs)[11].

Vitamin D has a number of potential roles for favorably altering the course of NAFLD (Figure 2), while it also improves the secretion and tissue sensitization to insulin[12]. The adipocyte is felt to be an important contributor to the pathogenesis of NAFLD. Vitamin D deficiency promotes adipocyte proinflammatory cytokines (adipokines), which are elevated in individuals with obesity, metabolic syndrome, and NAFLD, and are felt to contribute to disease[13,14]. Furthermore, vitamin D has been shown to upregulate adiponectin—an adipocyte-derived hormone. Adiponectin improves insulin sensitivity and prevents atherogenesis, which is decreased in those with obesity, metabolic syndrome, and NAFLD[15]. Vitamin D has been shown to inhibit hepatic inflammation and attenuates liver fibrosis in animal models[16]. Thus, the relationship of vitamin D deficiency to NAFLD pathogenesis merits careful analysis.

Numerous reports have revealed that patients with chronic liver disease from different etiologies had low vitamin D status[17-21]. In particular, liver diseases heralded by autoimmune or chronic inflammatory states appear to be worsened in the setting of vitamin D deficiency. In a pooled data meta-analysis, we recently showed that in nine of the 12 studies on mono-infected or co-infected patients with chronic hepatitis C, METAVIR stages three and four fibrosis were associated with profound 25-hydroxyvitamin D deficiency and the associated odds ratio (OR) and the 95% confidence interval (CI) were 1.88 (1.27, 2.77)[22]. There was substantial heterogeneity between studies as the total heterogeneity, I2, was 66.94%, thus indicating that there was substantial heterogeneity between studies[22].

A recent meta-analysis supports the contention that individuals with NAFLD with and without non-alcoholic steatohepatitis (NASH) are more prone to have hypovitaminosis D[23]. Wang *et al*[23] extracted data from 29 studies and reported that subjects with NAFLD had decreased 25-hydroxyvitamin D and were 1.26 times more likely to be vitamin D deficient. Individuals with inflammatory disease (NASH) have also been reported to have decreased levels of 25(OH)D. In support of our prior findings for chronic hepatitis C, recent studies have suggested that vitamin D levels are further decreased in advanced stages of fibrosis[24-26]. However, limitations have been observed regarding the criterion used to diagnose NAFLD, clinical variation in disease severity among the study groups, and inconsistency in defining vitamin D deficient states[9].

A number of investigations have attempted to link vitamin D status to histological disease activity and fibrosis of NAFLD[26-32]. Jaruvongvanich *et al*[33] systematically reviewed the literature to determine if vitamin D status was associated with NAFLD disease activity or fibrosis score and extracted data from six included studies involving 974 NAFLD subjects[33]. These investigators did not find a difference in the serum 25-hydroxyvitamin D levels among NAFLD patients with high histologic activity *vs* low, nor high fibrosis score *vs* low. In light of this finding, the investigators concluded that vitamin D status was not related to the histologic activity of NAFLD. In their study, Jaruvongvanich *et al*[33] did not assess the association of vitamin D levels across each precise stage of liver fibrosis based on liver biopsy in patients NAFLD.

In the current study, we determined the relationship between serum vitamin D status relative to the precise degree of hepatic fibrosis. Based on the METAVIR[34] system of histopathological staging in patients with NAFLD, we performed a systematic review and meta-analysis.

**MATERIALS AND METHODS**

***Literature search***

The present meta-analysis was performed according to the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements[35]. Applicable studies were identified by a library literature search using the Pubmed, Embase, Cochrane, and Web of Science databases by utilizing the PRISMA checklist from its inception to March 2017, then updated in September 2017. “Present a full electronic search strategy for at least one database, including any limits used, so that it could be repeated” and the Cochrane review reporting guidelines (6.6.2.2). The mesh terms for PubMed were as follows: "Non-alcoholic fatty liver disease", "Vitamin D", and "Liver cirrhosis". Also, the studies cited by the selected articles were searched for further pertinent studies. The details of the search strategy were prepared by the informationist (JN) in collaboration with the authors (Saberi B, Dadabhai AS and Mullin GE), as shown in Table 1.

***Study selection***

In the first phase, two separate reviewers carefully reviewed the abstract of the studies. When there was an agreement between two reviewers that a study fit the inclusion and exclusion criteria (Table 2), the article was then selected for further assessment. When there was a disagreement between the two reviewers, a third reviewer determined whether the study met the criteria for inclusion. Once the abstracts were included, the text was then carefully reviewed and data extraction was completed by at least two of the reviewers. The flowchart of the included studies is shown in Figure 3.

***Data extraction***

A total of six studies were included for extraction, which was performed by two independent reviewers (GM, BS) based on data quality, sufficiency, and relevance. Disagreements were resolved by a third reviewer (TS) to reach a consensus. The following data were extracted: last name of the first author, demographic information of patients, publication year, population, sample size, BMI, ALT, study design, method of vitamin D measurement, vitamin D levels in control and subjects, stage of fibrosis based on liver biopsy, and association of serum vitamin D level and fibrosis stage (Table 3). We then contacted the investigators of each study and collected the details of their data regarding serum vitamin D level measurements based on the stages of liver fibrosis (Tables 4 and 5). The methodologies utilized by the authors to assess the severity of fibrosis by METAVIR score are shown in Tables 6 and 7.

***Statistical analysis***

Statistical computations were conducted in R (Version 3.3.1, R Foundation for Statistical Computing, Vienna, Austria, 2016) 36 and Stata (Version 14, StataCorp, College Station, United States, 2017). In several studies, the mean and variance of vitamin D levels in the combined F0-F2 and F3-F4 fibrosis stage groups were unavailable in combined form despite multiple attempts from the authors; hence, the vitamin D levels were estimated using Monte Carlo simulations assuming vitamin D levels were normally distributed with the reported parameters for each fibrosis stage. For the meta-analysis of the comparisons between low fibrosis (F0-F2) *vs* high fibrosis (F3-F4), a random-effects meta-analysis fit using a restricted maximum likelihood (REML) was then fit using the metafor package in R. To assess associations across each fibrosis level, a meta-regression fit *via* REML was conducted using the metan and metareg functions in Stata. *P* < 0.05 was considered statistically significant[36]. The risk of publication bias across the included studies for all outcome measures was assessed by the construction of funnel plots.

**RESULTS**

***Study selection***

The search strategy utilized medical subject headings (MeSH) terms used to identify articles that evaluated serum vitamin D levels in patients with NAFLD based on the severity of liver fibrosis stage. Three hundred and thirty-seven articles were identified by PubMed (*n* = 56), EMBASE (*n* = 199), Cochrane (*n* = 13), and Web of Science (*n* = 69) search engines and one hundred and one duplicates were removed. Two independent reviewers provided a detailed evaluation of the articles assessed. This evaluation included data adequacy, criterion used to measure fibrosis, and overall pertinence to streamline for qualitative synthesis (Figure 3). All studies were cross-sectional. Table 2 summarizes the baseline characteristics, including the year of study, country, gender, population, BMI, Mean ALT (IU/L), vitamin D levels in NAFLD, and control patients. We then contacted investigators for the included studies and collected detailed data on vitamin D levels (Median or interquartile ranges; IQRs) based on the stage of fibrosis 4 (F0-F4). Out of the eight studies eligible for quantitative synthesis, we were able to gather and assemble vitamin D levels for each fibrosis stage category in a total of six studies (Tables 3-5). Based on this information on serum vitamin D levels, we then performed a quantitative synthesis across the six studies by performing a meta-analysis comparing F0-F2 (low fibrosis) *vs* F3-F4 (high fibrosis) groups and a meta-regression for the five categories of liver fibrosis (F0-F4).

***Definition of vitamin D levels***

Vitamin D status is based upon serum 25(OH)D values but this remains controversial. The most stable and plentiful metabolite of vitamin D in human serum, 25(OH)D has a half-life of about 3 wk, making it the most suitable indicator of vitamin D status[37]. The lower limit of normal was defined as being less than 30 ng/mL, thus serum 25(OH)D lower than 30 ng/mL defined insufficiency. Deficient serum vitamin D was defined by some investigators as 25(OH)D < 20 ng/mL while others used < 10 ng/mL as the cutoff. During the data extraction, we discovered that two of the studies did not use ng/mL to express serum 25(OH)D. Instead, the unit used was nmol/L to express serum 25(OH)D. Vitamin D insufficiency was defined as below the lower limit of normal (< 80 nmol/L).

***Association between vitamin D deficiency and the severity of liver disease***

Six included studies were cross-sectional analyses. A meta-analysis was conducted to compare the 25(OH) serum levels in patients with NAFLD according to the fibrosis stage (F0-F2 *vs* F3-F4) using a random-effects model. The results are shown in the Forest plot in Figure 4. We found no difference in the serum vitamin D levels according to high vs. low severity of hepatic fibrosis in subjects with NAFLD [(meta estimate mean difference = -0.86 (-4.17, 2.46)], *I*2 (total heterogeneity /total variability): 50.0%, *χ*2 = 9.95, df = 5, *P* value = 0.08]. The forest plot (Figure 4 and Supplemental Figure 1) also demonstrates heterogeneity among the six studies. The funnel plot in Figure 5 shows some asymmetry, thereby suggesting a limited publication bias within the studies. The NAFLD subjects in two of the eight relevant studies from the qualitative synthesis had significantly lower serum 25(OH)D in controls when compared to those with NAFLD[24,26].

We then further categorized the patients into five groups based on the stage of their fibrosis from F0-F4 (Table 4) and conducted a meta-regression, and found no association (*P* = 0.86, Supplementary Figure 2) between fibrosis stage and vitamin D levels across the six studies.

**DISCUSSION**

We examined the peer-reviewed literature of reports of NAFLD patients for an association of serum vitamin D with the stage of liver fibrosis by conducting a systematic review and meta-analysis. A total of eight cross-sectional studies underwent a full article review and were included for qualitative synthesis. We contacted the investigators of each study and collected details of their data regarding serum vitamin D level measurements based on the specific stage of liver fibrosis. Investigators from six of the eight included studies provided sufficient data to perform a quantitative analysis on a total of 937 subjects with the diagnosis of NAFLD. First, we performed a meta-analysis comparing 25(OH)D levels in subjects with high *vs* low stages of fibrosis (F0-F2 *vs* F3-F4). This association was not statistically significant [meta-estimate pooled mean difference= -0.86, *P* = 0.08 (-4.17, 2.46)]. These results were consistent with the findings by Jaruvongvanich *et al*[33] who reported that there was no difference in serum 25-hydroxyvitamin D levels among 974 NAFLD subjects across the same six studies. In their study, Jaruvongvanich *et al*[33] compared the high *vs* low histologic activity of NAFLD [pooled mean difference =-0.93 (-2.45, 0.58), *I*2 = 0%], and likewise, for the high *vs* low fibrosis score [pooled mean difference=0.88 (-2.65, 4.42), *I*2=64%][33]. They concluded that vitamin D status was not related to the histologic activity of NAFLD. We also conducted a meta-regression to determine whether there was an association between serum vitamin D levels and METAVIR stage of liver fibrosis (F0-F4) in NAFLD. As shown in Table 4, there are conflicting reports with three studies demonstrating significance (*P* < 0.05)[26,27,32] and three finding no association (*P* > 0.05)[28-30]. Our meta-regression did not find an association between vitamin D level and fibrosis stage across the studies.

As mentioned earlier, NAFLD encompasses a histological spectrum that encompasses a wide range of pathology. Hepatic steatosis, inﬂammation, ﬁbrosis, cirrhosis, and hepatocellular carcinoma are all possible consequences of NAFLD, and can even coexist in the same patient. It is well documented that a proportion of patients with NASH with liver inflammation will develop fibrosis, with this stage progressing over time from F0 to F4[38]. In a meta-analysis of patients with NAFLD, the proportion of fibrosis for stage 0 (35.8%), stage 1 (32.5%), stage 2 (16.7%), 3 (9.3%), and 4 (5.7%) respectively[39]. Patients with NASH and baseline F0 ﬁbrosis had an estimated annual fibrosis progression rate of 0.14 stages (95%CI, 0.07-0.21 stages), corresponding to 1 stage progression over 7.1 years for patients with NASH (95%CI, 4.8-14.3)[39]. It is well known that the major risk factors for NAFLD include obesity, insulin resistance, dyslipidemia, diabetes mellitus, and metabolic syndrome[38].

Vitamin D receptors (VDR) are expressed abundantly in the liver had have diverse consequences on metabolism which include the regulation of genes involved in glucose and lipid metabolism, and immunomodulation[40]. Low vitamin D has been reported to be strongly associated with insulin resistance[41]. Previous studies have estimated links between vitamin D and the development of NAFLD through various mechanisms that were recently reviewed by Eliades *et al*[9]. Vitamin D action on adipocytes and downregulates inflammatory cytokines IL-6, TNF-α and IL-1β through NF-κB pathway. Vitamin D also enhances the GLUT-4 receptor expression in myocytes, and also improves insulin utilization by increasing adiponectin secretion from adipocytes. Vitamin D downregulates the expression of various toll receptors in kupffer cells, thereby lessening inflammation caused by bacterial translocation (Figure 2)[9].

Also, researchers have noted vitamin D to have antifibrotic properties, as well as its involvement in the pathophysiology of liver fibrosis. The main cell involved in development of fibrosis in NAFLD is hepatic stellate cell (HSC). The HSCs become activated by losing their characteristic vitamin A droplets. Activated HSCs then produce an extracellular matrix, which leads to fibrosis and cirrhosis[42]. It is thought that the effect of vitamin D on the liver is complex but by binding to HSC VDR it reduces proliferation of these cells which play a major role in inducing fibrosis. It is known that liver nonparenchymal cells, including HSCs, express fully functional VDR, which has led many researchers to consider the vitamin D pathway as a possible modulator of liver fibrosis[43,44]. Ding *et al*[45] demonstrated that administration of the synthetic VDR agonist Calcipotriol ameliorated liver fibrosis in a standard mouse model of a Carbon Tetrachloride (CCL4) hepatic injury. Interestingly, they also showed that liver fibrosis was discovered in mice who have a genetic deletion of VDR, which strongly supports its role in hepatic homeostasis. Furthermore, activation of VDR signaling interferes with a wide range of transforming growth factor-beta (TGFβ)/SMAD)-dependent transcriptional responses on pro-fibrotic genes in HSCs[45].

In addition to the suggested mechanistic link between vitamin D and NAFLD, various clinical cohorts have shown the association of vitamin D and fibrosis in fatty liver disease patients. In a study by Nelso *et al*[31] 190 biopsy-proven NASH adults in the Non-alcoholic Steatohepatitis Clinical Research Network (NASHCRN) cohort were reviewed. The results demonstrate an independent association between serum 25-hydroxyvitamin D, increased NASH histological activity, and the presence of fibrosis. Although epidemiologic studies are promising in showing the association between low vitamin D levels and chronic liver disease, such as NAFLD, this study suggests that the current literature has a dearth of evidence to establish causality between vitamin D and the histopathologic stage of liver fibrosis[8]. Some of the recent studies raised doubts regarding a causal link between vitamin D deficiency and non-skeletal health outcomes reviewing prospective studies and clinical trials, thereby suggesting that having a vitamin D deficiency is a predictor rather than the cause of the disease[46]. Well-designed prospective randomized clinical trials are needed to better understand the influence the oral intake (food and supplement) of vitamin D to the point of sufficiency on disease progression in NAFLD patients.

A few clinical trials using small numbers of study subjects have evaluated the effect of vitamin D supplementation in patients with NAFLD. These studies should be interpreted with caution, given the small sample sizes and short course of follow up. In a small double-blind, placebo-control trial study, NAFLD patients were randomly assigned to receive vitamin D (50000 IU every 14 d for 4 mo) *vs* placebo[47]. The period of 4 mo was used as the benchmark for analysis of results. The authors reported that the serum levels of liver chemistries, homeostatic model assessment for insulin resistance (HOMA-IR), or grades of hepatic steatosis as measured by ultrasound, were not at variance (vitamin D *vs* placebo)[47].

In a more recent study, a 12-wk, randomized, controlled, double-blind trial was conducted on 120 NAFLD patients randomly assigned to three groups. Each patient received 25 µg calcitriol (*n* = 37), 500 mg calcium carbonate, plus 25 µg calcitriol (*n* = 37) or placebo (*n* = 36) every day following a weight-loss program. Serum insulin and HOMA-IIR significantly reduced in subjects who received vitamin D compared to control group. Adjusting to the baseline measurements, the patients who received vitamin D showed a signiﬁcant decrease in ALT and stage of fat, as evaluated by liver ultrasound following 12 wk of intervention[48]. In another small, clinical, double-blind, placebo-controlled trial on patients with NAFLD and type 2 diabetes from Italy, there was no significant difference found between patients who received 24 weeks of vitamin D *vs* placebo in terms of primary endpoint, hepatic fat fraction (HFF) measured by MRI, nor hepatic outcomes, such as liver enzymes, CK18, and Fatty Liver Index (FLI)[49]. Most of these studies evaluated markers of inflammation and degree of fat, but not the degree of fibrosis, except for the clinical trial by Corte *et al*[50] which studied 41 pediatrics patients who were enrolled to receive docosahexanoic acid (DHA) and vitamin D *vs* placebo. All patients had a liver biopsy diagnosing NAFLD at the beginning of the study. Furthermore, patients on the treatment arm also received liver biopsy at completion. The combination of vitamin D and docosahexaenoic acid treatment reduced the nonalcoholic fatty liver disease activity score (NAS) in the treatment group[50]. These investigators reported a reduction of the activation of HSC and fibril-forming collagen but not fibrosis score in the treatment group. Moreover, the ALT and HOMA-IR were all decreased with treatment[50]. A meta-analysis of seven clinical trials of vitamin D supplementation with 452 participants concluded that Vitamin D supplementation did not affect a number of markers associated with insulin resistance such as triglycerides, total-, LDL-cholesterol, FPG, insulin, HOMA-IR, AST, ALT, and BMI[51].

Finally, hepatic inflammatory processes, such as NASH, are known to deplete 25(OH)D levels and promote oxidative stress and other mediators, which contribute to progressive fibrogenesis and resistance to supplementation with vitamin D[51,52].

There are a number of noteworthy limitations to this meta-analysis. The included studies in the meta-analysis are all cross-sectional studies. Observational research is not enough to support a causal link between vitamin D and severity of liver disease, unless it is supported by evidence from randomized controlled trials. If the beneﬁts are not reproduced in randomized trials, then the relation between vitamin D and NAFLD is probably the result of confounding or physiological events involved in these disorders[46]. There was heterogeneity among the included patient population in the studies. The BMI was variable among the studies, and particularity patients included in the study by Targher had a mean BMI of 26.3 that was significantly lower than others[26]. The evaluation of the stage of fibrosis is usually made through NASH clinical trial research network scoring system (Table 6)[53]. In two of the six included studies in the meta-analysis, Tragher and Barchetta used the liver fibrosis staging system developed by Brunt *et al*[54], which is slightly different from the NASH clinical trial research network scoring system (Tables 6 and 7). Our study was not adjusted for other confounders of metabolic syndrome, such as diabetes, obesity, and insulin resistance. Moreover, our study did not evaluate other factors that can affect vitamin D levels such as diet, circadian rhythm and season. Studies have shown that serum vitamin D levels are higher in individuals who use diet high in: dairy products, fatty fish and vitamin D supplementation. Vitamin D is directly associated with sun exposure and the serum levels of vitamin D is lower in winters[55].

In summary, prior studies have illustrated that vitamin D may be involved in the pathogenesis of NAFLD. However, in this meta-analysis, we found no evidence that the progression of fibrosis in subjects with NALFD is linked to low vitamin D status. These data are consistent with the aforementioned failure of clinical trials using vitamin D supplementation to improve NAFLD.

**ARTICLE HIGHLIGHTS**

***Research background***

Vitamin D is a hormone and a vitamin combined that appears to effects cells throughout the body and impart abundant health benefits. There are many studies on its potential role in modifying chronic liver disease. Given the escalating prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide, we studied the world’s literature for the association of vitamin D serum levels and progression of scar tissue formation in NAFLD.

***Research motivation***

The goal of a systematic review is to pull together the peer-reviewed literature and then apply standardized guidelines to extract the papers that used proper methodology. In this instance, we sorted through 337 papers to find the relevant peer-reviewed manuscripts of sufficient quality to provide scientific truth on this subject matter.

***Research objectives***

The primary objective was to determine whether there was an association of serum vitamin D and the degree of scar tissue in the liver.

***Research methods***

We followed international guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses in systematically analyzing the 337 articles with duplicate screening and extraction by the authors. The authors contacted investigators of previous papers to report crucial data not stated in their manuscripts. An expert biostatistician assisted with data analysis by using Cochrane RevMan 5 software.

***Research results***

We discovered that only six of the 337 studies have sufficient data to be included in the data-synthesis part of the analysis, also known as meta-analysis. We did not find an association of serum vitamin D with the degree of liver scarring in NAFLD.

***Research conclusions***

Our biostatistician applied advanced methodologies to determine the relationship of the individual stages of liver scarring to serum vitamin D levels called meta-regression. We observed that serum vitamin D was not associated with liver scar tissue accumulation irrespective of the phase of hepatic injury. In February 2017, we reported in *World Journal of Hepatology* that there was an association between the degrees of scar tissue formation in chronic Hepatitis C with the serum level of vitamin D. Given that vitamin D appears to have a strong influence on immunity and wound healing, it is still possible that supplemental vitamin D to normal levels could help prevent liver disease progression in NAFLD. Interventional trials would be best suited to explore this possibility. This study further elucidated that serum vitamin D does not appear to be associated with the stage of liver scar tissue accumulation.Application of meta-regression permits an analysis of the individual phases of liver scar tissue formation in association with the serum levels of vitamin D. This meta-analysis utilized novel data synthesis and statistical inquiry to report with confidence that the degree of liver scarring is not relatable to the serum vitamin D status. Vitamin D when given to individuals with NAFLD having no to little liver scarring may prevent progressive accumulation. Intervention with vitamin D supplements and enriched foods (*i.e.*, dairy, salmon) to normal serum levels with no or low levels of liver scarring in NAFLD to prevent disease progression. Utilization of the biostatistical method of meta-regression of data reporting the individual stages of scar tissue formation in relation to the status of serum vitamin D. We confirmed the null hypothesis (N0) that there was “no effect” of vitamin D on liver scar tissue severity. The term “null” is used in biostatics to represent the hypothesis that there is no effect or influence of an intervention upon an outcome. We anticipated that the null hypothesis would be rejected in this study and the opposite occurred. Clinicians should bear in mind that many patients with nonalcoholic fatty liver disease are obese and have lower serum vitamin D levels than non-obese subjects due to sequestration into adipose tissues. Thus, supplementation with vitamin D3 to sufficient levels should be considered.

***Research perspectives***

When conducting a meta-regression, there may be crucial data that is unavailable in the paper that does require proactive investigation by researchers to uncover the scientific truth. Mistakes in the reporting of research papers occur, and a careful meta-analysis can help the scientific community by providing a higher level of accountability. Interventional trials with vitamin D supplements involving subjects with established NAFLD. Systematic reviews and synthesis, as in our paper, should employ vigilance in data extraction and contact the authors of relevant prior works to obtain further information about missing data, statistical analysis, and to clarify methods. As in our paper, acknowledgment of authors who cooperate with the provision of information for systematic review and synthesis should be noted in the resulting manuscript.

**REFERENCES**

1 **Sayiner M**, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. *Clin Liver Dis* 2016; **20**: 205-214 [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001]

2 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

3 **Do A,** Lim JK. Epidemiology of nonalcoholic fatty liver disease: A primer. *Clinical Liver Disease* 2016 [DOI: 10.1002/cld.547]

4 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]

5 **Rinella ME**. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015; **313**: 2263-2273 [PMID: 26057287 DOI: 10.1001/jama.2015.5370]

6 **Wong RJ**, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015; **148**: 547-555 [PMID: 25461851]

7 **Holick MF**. Vitamin D deficiency. *N Engl J Med* 2007; **357**: 266-281 [PMID: 17634462 DOI: 10.1056/NEJMra070553]

8 **Iruzubieta P**, Terán Á, Crespo J, Fábrega E. Vitamin D deficiency in chronic liver disease. *World J Hepatol* 2014; **6**: 901-915 [PMID: 25544877 DOI: 10.4254/wjh.v6.i12.901]

9 **Eliades M**, Spyrou E. Vitamin D: a new player in non-alcoholic fatty liver disease? *World J Gastroenterol* 2015; **21**: 1718-1727 [PMID: 25684936 DOI: 10.3748/wjg.v21.i6.1718]

10 **Cantorna MT**. Mechanisms underlying the effect of vitamin D on the immune system. *Proc Nutr Soc* 2010; **69**: 286-289 [PMID: 20515520 DOI: 10.1017/S0029665110001722]

11 **Mocanu V**, Oboroceanu T, Zugun-Eloae F. Current status in vitamin D and regulatory T cells--immunological implications. *Rev Med Chir Soc Med Nat Iasi* 2013; **117**: 965-973 [PMID: 24502077]

12 **Alkharfy KM**, Al-Daghri NM, Yakout SM, Hussain T, Mohammed AK, Krishnaswamy S. Influence of vitamin D treatment on transcriptional regulation of insulin-sensitive genes. *Metab Syndr Relat Disord* 2013; **11**: 283-288 [PMID: 23621113 DOI: 10.1089/met.2012.0068]

13 **Adolph TE**, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. *Int J Mol Sci* 2017; **18**: pii: E1649[PMID: 28758929 DOI: 10.3390/ijms18081649]

14 **Carlberg C**. Genome-wide (over)view on the actions of vitamin D. *Front Physiol* 2014; **5**: 167 [PMID: 24808867 DOI: 10.3389/fphys.2014.00167]

15 **Banerjee A**, Khemka VK, Roy D, Poddar J, Roy TKS, Karnam SA. Role of Serum Adiponectin and Vitamin D in Prediabetes and Diabetes Mellitus. *Can J Diabetes* 2017; **41**: 259-265 [PMID: 28236525]

16 **Abramovitch S**, Sharvit E, Weisman Y, Bentov A, Brazowski E, Cohen G, Volovelsky O, Reif S. Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis. *Am J Physiol Gastrointest Liver Physiol* 2015; **308**: G112-G120 [PMID: 25214398 DOI: 10.1152/ajpgi.00132.2013]

17 **Arteh J**, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. *Dig Dis Sci* 2010; **55**: 2624-2628 [PMID: 19960254 DOI: 10.1007/s10620-009-1069-9]

18 **Terrier B**, Carrat F, Geri G, Pol S, Piroth L, Halfon P, Poynard T, Souberbielle JC, Cacoub P. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. *J Hepatol* 2011; **55**: 756-761 [PMID: 21334402 DOI: 10.1016/j.jhep.2011.01.041]

19 **Farnik H**, Bojunga J, Berger A, Allwinn R, Waidmann O, Kronenberger B, Keppler OT, Zeuzem S, Sarrazin C, Lange CM. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. *Hepatology* 2013; **58**: 1270-1276 [PMID: 23703797 DOI: 10.1002/hep.26488]

20 **Efe C**, Kav T, Aydin C, Cengiz M, Imga NN, Purnak T, Smyk DS, Torgutalp M, Turhan T, Ozenirler S, Ozaslan E, Bogdanos DP. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. *Dig Dis Sci* 2014; **59**: 3035-3042 [PMID: 25002309 DOI: 10.1007/s10620-014-3267-3]

21 **Franco AS**, Freitas TQ, Bernardo WM, Pereira RMR. Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis. *Medicine* (Baltimore)2017; **96**: e7024 [PMID: 28591033 DOI: 10.1097/MD.0000000000007024]

22 **Dadabhai AS**, Saberi B, Lobner K, Shinohara RT, Mullin GE. Influence of vitamin D on liver fibrosis in chronic hepatitis C: A systematic review and meta-analysis of the pooled clinical trials data. *World J Hepatol* 2017; **9**: 278-287 [PMID: 28261385 DOI: 10.4254/wjh.v9.i5.278]

23 **Wang X**, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. *Int J Clin Exp Med* 2015; **8**: 17221-17234 [PMID: 26770315]

24 **Dasarathy J**, Periyalwar P, Allampati S, Bhinder V, Hawkins C, Brandt P, Khiyami A, McCullough AJ, Dasarathy S. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. *Liver Int* 2014; **34**: e118-e127 [PMID: 24118743 DOI: 10.1111/liv.12312]

25 **Liangpunsakul S**, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. *Dig Dis Sci* 2011; **56**: 2124-2129 [PMID: 21503677 DOI: 10.1007/s10620-011-1707-x]

26 **Targher G**, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutr Metab Cardiovasc Dis* 2007; **17**: 517-524 [PMID: 16928437 DOI: 10.1016/j.numecd.2006.04.002]

27 **Anty R**, Hastier A, Canivet CM, Patouraux S, Schneck AS, Ferrari-Panaia P, Ben-Amor I, Saint-Paul MC, Gugenheim J, Gual P, Iannelli A, Tran A. Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients. *Obes Surg* 2016; **26**: 2138-2143 [PMID: 26787197 DOI: 10.1007/s11695-016-2070-y]

28 **Barchetta I**, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. *Hepatology* 2012; **56**: 2180-2187 [PMID: 22753133 DOI: 10.1002/hep.25930]

29 **Bril F**, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A, Cusi K. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. *J Hepatol* 2015; **62**: 405-411 [PMID: 25195551 DOI: 10.1016/j.jhep.2014.08.040]

30 **Luger M**, Kruschitz R, Kienbacher C, Traussnigg S, Langer FB, Schindler K, Würger T, Wrba F, Trauner M, Prager G, Ludvik B. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. *Obes Surg* 2016; **26**: 2425-2432 [PMID: 26989059 DOI: 10.1007/s11695-016-2123-2]

31 **Nelson JE**, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-Stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV. Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB? *Am J Gastroenterol* 2016; **111**: 852-863 [PMID: 27002799 DOI: 10.1038/ajg.2016.51]

32 **Patel YA**, Henao R, Moylan CA, Guy CD, Piercy DL, Diehl AM, Abdelmalek MF. Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. *Am J Gastroenterol* 2016; **111**: 1591-1598 [PMID: 27644736 DOI: 10.1038/ajg.2016.406]

33 **Jaruvongvanich V**, Ahuja W, Sanguankeo A, Wijarnpreecha K, Upala S. Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis. *Dig Liver Dis* 2017; **49**: 618-622 [PMID: 28274829 DOI: 10.1016/j.dld.2017.02.003]

34 **Mohamadnejad M**, Tavangar SM, Sotoudeh M, Kosari F, Khosravi M, Geramizadeh B, Montazeri G, Estakhri A, Mirnasseri MM, Fazlollahi A, Zamani F, Malekzadeh R. Histopathological Study of Chronic Hepatitis B: A Comparative Study of Ishak and METAVIR Scoring Systems. *Int J Organ Transplant Med* 2010; **1**: 171-176 [PMID: 25013582]

35 **Knobloch K**, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. *J Craniomaxillofac Surg* 2011; **39**: 91-92 [PMID: 21145753 DOI: 10.1016/j.jcms.2010.11.001]

36 **R Foundation for Statistical Computing.** A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014

37 **Thacher TD**, Clarke BL. Vitamin D insufficiency. *Mayo Clin Proc* 2011; **86**: 50-60 [PMID: 21193656 DOI: 10.4065/mcp.2010.0567]

38 **Satapathy SK**, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. *Semin Liver Dis* 2015; **35**: 221-235 [PMID: 26378640 DOI: 10.1055/s-0035-1562943]

39 **Singh S**, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol* 2015; **13**: 643-654. e1-9; quiz e39-40 [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014]

40 **Chun RF**, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: lessons learned from genome-wide analysis. *Front Physiol* 2014; **5**: 151 [PMID: 24795646 DOI: 10.3389/fphys.2014.00151]

41 **Pittas AG**, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007; **92**: 2017-2029 [PMID: 17389701 DOI: 10.1210/jc.2007-0298]

42 **Friedman SL**. Liver fibrosis -- from bench to bedside. *J Hepatol* 2003; **38** Suppl 1: S38-S53 [PMID: 12591185]

43 **Ding N**, Liddle C, Evans RM, Downes M. Hepatic actions of vitamin D receptor ligands: a sunshine option for chronic liver disease? *Expert Rev Clin Pharmacol* 2013; **6**: 597-599 [PMID: 24164608 DOI: 10.1586/17512433.2013.841078]

44 **Gascon-Barré M**, Demers C, Mirshahi A, Néron S, Zalzal S, Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. *Hepatology* 2003; **37**: 1034-1042 [PMID: 12717384 DOI: 10.1053/jhep.2003.50176]

45 **Ding N**, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. *Cell* 2013; **153**: 601-613 [PMID: 23622244 DOI: 10.1016/j.cell.2013.03.028]

46 **Autier P**, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. *Lancet Diabetes Endocrinol* 2014; **2**: 76-89 [PMID: 24622671 DOI: 10.1016/S2213-8587(13)70165-7]

47 **Sharifi N**, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. *Endocrine* 2014; **47**: 70-80 [PMID: 24968737 DOI: 10.1007/s12020-014-0336-5]

48 **Lorvand Amiri H**, Agah S, Mousavi SN, Hosseini AF, Shidfar F. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial. *Arch Iran Med* 2016; **19**: 631-638 [PMID: 27631178 DOI: 10.0161909/AIM.006:]

49 **Barchetta I**, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *BMC Med* 2016; **14**: 92 [PMID: 27353492 DOI: 10.1186/s12916-016-0638-y]

50 **Della Corte C**, Carpino G, De Vito R, De Stefanis C, Alisi A, Cianfarani S, Overi D, Mosca A, Stronati L, Cucchiara S, Raponi M, Gaudio E, Byrne CD, Nobili V. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. *PLoS One* 2016; **11**: e0168216 [PMID: 27977757 DOI: 10.1371/journal.pone.0168216]

51 **Dasarathy J**, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. *J Nutr* 2017; **147**: 1938-1946 [PMID: 28814531 DOI: 10.3945/jn.117.254292]

52 **Mathieu C.** Vitamin D and the immune system: Getting it right. I. BMS BONEKEY 2011: 178. April 11**,**2011 [DOI: 10.1138/20110505]

53 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]

54 **Brunt EM**, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999; **94**: 2467-2474 [PMID: 10484010 DOI: 10.1111/j.1572-0241.1999.01377.x]

55 **Klingberg E**, Oleröd G, Konar J, Petzold M, Hammarsten O. Seasonal variations in serum 25-hydroxy vitamin D levels in a Swedish cohort. *Endocrine* 2015; **49**: 800-808 [PMID: 25681052 DOI: 10.1007/s12020-015-0548-3]

**P-Reviewer:** Carvalho-Filho RJ, Cichoz-Lach H, Serban ED, Tanaka N **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**


Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor):E




**Figure 1 The immunomodulatory effects of 1,25(OH)2D3.** 1,25(OH)2D3 targets different players of the innate and adaptive immune compartment. 1,25(OH)2D3 stimulates innate immune responses by enhancing the chemotactic and phagocytotic responses of macrophages, as well as the production of antimicrobial proteins such as cathelicidin. On the other hand, 1,25(OH)2D3 also modulates adaptive immunity. At the level of the APC (like the DC), 1,25(OH)2D3 inhibits the surface expression of the MHC-II-complexed antigen and co-stimulatory molecules, in addition to the production of the cytokines IL-12 and IL-23, thereby indirectly shifting the polarization of T cells from a Th1 and Th17 phenotype towards a Th2 phenotype. In addition, 1,25(OH)2D3 directly affects T cell responses, by inhibiting the production of Th1 cytokines (IL-2 and IFN-γ) and Th17 cytokines (IL-17 and IL-21), and by stimulating Th2 cytokine production (IL-4). Moreover, 1,25(OH)2D3 favors Treg cell development *via* modulation of DCs and by directly targeting T cells. Finally, 1,25(OH)2D3 blocks plasma cell differentiation, IgG and IgM production, and B cell proliferation. Reproduced with the permission of the Nature Publishing Group[53].




**Figure 2 Schematic representation of metabolic, anti-inflammatory, and anti-fibrotic effects of vitamin D on hepatocytes and non-parenchymal hepatic cells (hepatic stellate cells, Kupffer cells) in non-alcoholic fatty liver disease**. Left: At the initial stage of lipogenesis, 1,25(OH)D acts on adipocytes and inhibits NF-κB transcription, known as the pro-inflammatory “master switch”, and thus inhibits the expression of the inflammatory cytokines IL-6, TNF-α, and IL-1β. It also increases adiponectin secretion from adipocytes and enhances GLUT-4 receptor expression in myocytes, both of which improve insulin resistance; Middle: Increased gut permeability allows the translocation of bacterial pathogens which can activate Toll-like receptors (TLR) on Kupffer cells. 1,25(OH)D downregulates the expression of TLR-2, TLR-4, and TLR-9 in these cells, thus ameliorating inflammation; Right: 1,25(OH)D acts on hepatic stellate cells by binding to VDR, which reduces the proliferation of these cells that play a major role in inducing fibrosis. VDR: Vitamin D receptor; TLR: Toll-like receptor; LPS: Lipopolysaccharide. Reproduced in compliance with Creative Commons in PubMed Central Open Access.



**Figure 3 Flowchart illustrating the process for the selection of the included articles.** Three hundred and thirty-seven articles were identified using PubMed (*n* = 56)/EMBASE (*n* = 199)/Cochrane (*n* = 13)/Web of Science (*n* = 69) search engines. A detailed evaluation of the articles by at least two independent reviewers (total of three) assessed the sufficiency of data, the method of fibrosis qualification, and relevance to the topic in order to narrow the studies to six.



**Figure 4 Random effects pooled the mean difference of 25-hydroxyvitamin D levels in nonalcoholic fatty liver disease patients with high and low fibrosis scores.** A meta-analysis of the pooled data of the six included studies according to METAVIR fibrosis scores of low F0-2 *vs* high F3-4. Figure 4 illustrates the forest plot of the results of the six included studies, with 95%CI, and the overall effect (under the random-effects model) with 95%CI are illustrated in this forest plot. The six included studies[26-30,32] assessed the association of 25-hydroxyvitamin D among patients with nonalcoholic fatty liver disease (NAFLD). We used a random-effects model to assess the pooled data in a meta-analysis as previously described[36].The statistical heterogeneity was not significant with *I*2 of 37.8% (Pheterogeneity=0.0766); however, we observed a trend towards high heterogeneity. We found no difference in 25-hydroxyvitamin D among NAFLD patients with high (F3-4) *vs* low (F0-2) fibrosis, with the summary effect size of 0.95 representing mean differences between F0-2 and F3-4 NAFLD patients. Overall, our analysis confirmed that there was no association between serum 25-hydroxyvitamin D and METAVIR low *vs* high score in NAFLD patients from the six included studies.



**Figure 5 Funnel plot of standard error by differences in Means for 25(OH)D.** We analyzed the data for a possible publication bias. The circles represent observed published studies. The funnel plot was asymmetric, thereby suggesting a possible publication bias.

**Table 1 Search results of vitamin D and non-alcoholic fatty liver disease**

|  |  |  |
| --- | --- | --- |
| **Database/search** | **Search terms** | **Search results** |
| EMBASE |  |  |
| 1 | (‘liver cirrhosis’/exp OR cirrhosis: ti, ab OR cirrhoses: ti, ab OR fibrosis: ti, ab OR fibroses: ti, ab) |  |
| 2 | (‘vitamin D’/exp OR ‘25 hydroxyvitamin d’/exp OR ‘vitamin d’: ti, ab OR ‘ergocalciferols’: ti, ab OR ’ergocalciferol’: ti, ab OR ‘25 hydroxy vitamin d’: ti,ab OR ‘25 hydroxyvitamin d’:ti, ab OR ’25 hydroxy d’: ti, ab OR ‘25(OH)D’: ti, ab OR ‘25-hydroxyvitamin d 2’: ti, ab) |  |
| 3 | (‘nonalcoholic fatty liver’/exp OR ‘Non-alcoholic Fatty Liver’: ti, ab OR ‘nonalcoholic fatty liver’:ti, ab OR ’Non-alcoholic Fatty Livers’: ti, ab OR ‘nonalcoholic fatty livers’:ti, ab OR ’NAFLD’:ti, ab OR ‘NASH’:ti, ab OR ’nonalcoholic steatohepatitis’: ti, ab OR ‘nonalcoholic steatohepatitides’:ti,ab OR ’fatty liver’/de OR ’fatty liver’:ti, ab OR ‘Steatohepatitis’:ti, ab OR ‘Steatosis of Liver’:ti, ab OR ‘Liver Steatosis’: ti, ab OR ‘Liver Steatoses’: ti, ab OR ‘hepatic steatosis’: ti, ab OR ‘hepatosteatosis’: ti, ab) |  |
| 4 | 1 and 2 and 3 | 199 |
| Web of science |  |  |
| 1 | ("Non-alcoholic Fatty Liver" OR "nonalcoholic fatty liver" OR "Non-alcoholic Fatty Livers" OR "nonalcoholic fatty livers" OR "NAFLD" OR "NASH" OR "nonalcoholic steatohepatitis" OR "fatty liver" OR Steatohepatitis OR "Steatosis of Liver" OR "Liver Steatosis" OR "Liver Steatoses" OR "hepatic steatosis" OR "hepatosteatosis") |  |
| 2 | ("liver cirrhosis" OR cirrhosis OR cirrhoses OR fibroses OR fibrosis) |  |
| 3 | ("vitamin d" OR "ergocalciferols" OR "ergocalciferol" OR "25 hydroxy vitamin d" OR "25 hydroxyvitamin d" OR "25 hydroxy d" OR "25(OH)D" OR "25-hydroxyvitamin d 2") |  |
| 4 | 1, 2 and 3 | 69 |
| Cochrane |  |  |
| 1 | MeSH descriptor: [Non-alcoholic Fatty Liver Disease] explode all trees | 181 |
| 2 | MeSH descriptor: [Liver Cirrhosis] explode all trees | 2462 |
| 3 | MeSH descriptor: [Vitamin D] explode all trees | 2907 |
| 4 | "Non-alcoholic Fatty Liver" or "nonalcoholic fatty liver" or "Non-alcoholic Fatty Livers"  or "nonalcoholic fatty livers" or "NAFLD" or "NASH" or "nonalcoholic steatohepatitis"  or "fatty liver" or Steatohepatitis or "Steatosis of Liver" or "Liver Steatosis" or  "Liver Steatoses" or "hepatic steatosis" or"hepatosteatosis":ti, ab, kw | 1470 |
| 5 | "liver cirrhosis" or cirrhosis or cirrhosis or fibrosis or fibroses:ti,ab,kw | 13273 |
| 6 | "vitamin d" or "ergocalciferols" or "ergocalciferol" or "25 hydroxy vitamin d"  or "25 hydroxyvitamin d" or "25 hydroxy d" or "25(OH)D"  or "25-hydroxyvitamin d 2":ti,ab,kw | 6061 |
| 7 | 1 or 4 | 1470 |
| 8 | 2 or 5 | 13273 |
| 9 | 3 or 6 | 6722 |
| 10 | 7 and 8 and 9 | 13 |
| PubMed |  |  |
| 1 | (("Non-alcoholic Fatty Liver Disease"[Mesh] OR "Non-alcoholic Fatty Liver"[tw] OR "nonalcoholic fatty liver"[tw] OR "Non-alcoholic Fatty Livers"[tw] OR "nonalcoholic fatty livers"[tw] OR "NAFLD"[tw] OR "NASH"[tw] OR "nonalcoholic steatohepatitis"[tw] AND "Fatty Liver"[Mesh:noexp] OR "fatty liver"[tw] OR Steatohepatitis[tw] OR "Steatosis of Liver"[tw] OR "Liver Steatosis"[tw] OR "Liver Steatoses"[tw] OR "hepatic steatosis"[tw] OR "hepatosteatosis"[tw]) |  |
| 2 | ("vitamin d"[mh] OR "vitamin d"[tw] OR "ergocalciferols"[tw] OR "ergocalciferol"[tw] OR "25 hydroxy vitamin d"[tw] OR "25 hydroxyvitamin d"[tw] OR "25 hydroxy d"[tw] OR "25(OH)D"[tw] OR "25-hydroxyvitamin d 2"[tw]) |  |
| 3 | ("liver cirrhosis"[mh] OR cirrhosis[tw] OR cirrhoses[tw] OR fibrosis[tw] OR fibroses[tw]) |  |
| 4 | 1 and 2 and 3 | 56 |
|  |  | Search results |
|  | Total | 337 |
|  | Duplicated | 101 |
|  | Final total | 226 |

**Table 2 Inclusion and exclusion criteria of studies on vitamin D in non-alcoholic fatty liver disease**

|  |
| --- |
| **Inclusion criteria** |
| (1)Patients ≥ 18 yr |
| (2) Studies that evaluated vitamin D in NAFLD |
| (3) Studies that evaluated the liver fibrosis stage, only based on liver biopsy |
| (4) Studies that reported serum or plasma 25(OH)D levels |
| Exclusion criteria |
| (1) Age < 18 yr |
| (2) Liver diseases other than NAFLD |
| (3) Studies that used non-invasive methods to evaluate liver fibrosis |
| (4) Studies with inadequate data |

25-OH(D): 25-hydroxyvitamin D; NAFLD: Nonalcoholic fatty liver disease.

**Table 3 Characteristics of patients’ studies for vitamin D status in non-alcoholic fatty liver disease**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Citation** | **Patel *et al*[32]** | **Luger *et al*[30]** | **Barchetta *et al*[28]** | **Anty *et al*[27]** | **Dasarthy *et al*[24]** | **Bril *et al*[30]** | **Nelson *et al*[31]** | **Targher *et al*[26]** |
| Year | 2016 | 2016 | 2012 | 2016 | 2014 | 2015 | 2016 | 2007 |
| Country | United States | Austria | Italy | France | United States | United States | United States | Italy |
| Subjects (M,F) | 293 (195,98) | 50 (10, 40) | 45 (22, 23) | 398 (64, 334) | 187 (51, 136) | 239 (204, 35) | 190 (89, 101) | 120 (80,40) |
| Population | Suspected NAFLD undergoing liver biopsy | Gastric bypass patients | Suspected NAFLD | Morbidly obese referred for bariatric surgery | Biopsy proven NAFLD, normal controls | Overweight patients | Biopsy proven NAFLD | Biopsy proven NAFLD |
| Mean BMI  Subjects | 36.1 ± 7.8  NAFLD | 43.8 ± 4.3  All | 30.5 ± 5.5  NASH | 42.8 ± 5.0  All | 35.7 ± 7.0  NAFLD | 34.6 ± 0.4  NASH | 35.6 ± 10.8  NAFLD | 26.3 ± 2.0  NAFLD |
| Mean ± SD ALT IU/L  Subjects | 66.5 +/- 51.2 NAFLD | 36.4 ± 20.8  All | 87.5 ± 46.6  NASH | 35.2+/-24.5  Morbidly Obese | 45.9 ± 30.0  NAFLD | 64.0 ± 4.0  NASH | 77.0 ± 48.2  NAFLD | 105 ± 42.0  NAFLD |
| Study design | Cross sectional | Cross sectional | Cross sectional | Cross sectional | Cross sectional | Cross sectional | Cross sectional | Cross sectional |
| Vitamin D analysis | CLIA | Not described | CLIA | CLIA | CLIA | CLIA | GC-MS | CLIA |
| Mean/SD 25(OH)D (ng/mL), (*n*)  subjects | 27.6 ± 11.8 | 15.6 ± 5.6 | 22.0 ± 12.4 | 19.2 +/-9.0 | 21.2 ± 10.4 | 21.8 +/- 1.0 | 20.9 ± 4.0 | 20.4 +/-8.8 |
| Mean/SD 25(OH)D (ng/mL) Non-NAFLD Controls | 27.9 ± 12.8 | NA | 52.9 ± 11.02 | 21.5 ± 10/2 | 35.7 ± 6.0 | 24.5 ± 2.1 | NA | 30.0 ± 6.0 |
| *P* value; NAFLD *vs* controls | 0.878 | NA | Not significant | 0.13 | < 0.01 | 0.18 | NA | < 0.001 |

*n*: Number of subjects; 25-OH(D): 25-hydroxylvitamin D; SD: Standard deviation; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; BMI: Body mass index; CLIA: Chemiluminescence; GC-MS: Gas chromatography mass spectroscopy; M: Male; F: Female.

**Table 4 Relationship of vitamin D to liver fibrosis in non-alcoholic fatty liver disease**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author/year/**  **Ref** | **(*n*), 25-OH(D) Mean ± SD**  **F0** | **(*n*), 25-OH(D)**  **Mean ±**  **SD**  **F1** | **(*n*), 25-OH(D)**  **Mean ±**  **SD**  **F2** | **(*n*), 25-OH(D)**  **Mean ±**  **SD**  **F3** | **(*n*), 25-OH(D)**  **Mean ±**  **SD**  **F4** | ***P* value** |
| Patel *et al*[32]  2016 | (39)  24.4 ± 10.4 | (78)  26.5 ± 8.9 | (55)  29.1 ± 12.5 | (63)  30.7 ± 14.1 | (9)  20.2 ± 20.2 | 0.028 |
| Targher *et al*[26]  2007 | (16)  20.8 ± 8.4 | (10)  14.4 ± 9.2 | (7)  10.0 ± 10.0 | (6)  6.0 ± 10.8 | 0 | 0.01 |
| Anty *et al*[27]  2016 | (50)  20.04 ± 7.81 | (233)  19.91 ± 9.12 | (98)  18.28 ± 9.58 | (15)  16.71 ± 9.86 | (2)  25 ± 10.18 | 0.01 |
| Luger *et al*[30]  2016 | (2)  15.6 ± 5.2 | (30)  15.2 ± 6.0 | (8)  15.6 ± 4.4 | (4)  17.6 ± 7.6 | (2)  20.4 ± 4.4 | 0.792 |
| Bril *et al*[29]  2015 | (61)  20.5 ± 10.4 | (75)  24.2 ± 15.1 | (22)  20.8 ± 12.1 | (22)  25.5 ± 12.2 | (5)  21.1 ± 6.9 | 0.27 |
| Barchetta *et al*[28]  2012 | (1)  20.5 | (10) 23.5 ± 14.4 | (7)  16.25 ± 6.1 | (6)  28.8 ± 14.9 | (1)  17.3 | 0.56 |

*n*: Number of subjects; 25-OH(D): 25-hydroxylvitamin D; SD: Standard deviation; F0-F4: Severity score of hepatic fibrosis.

**Table 5 Relationship of vitamin D to liver fibrosis in non-alcoholic fatty liver disease by high *vs* low fibrosis score**

|  |  |  |
| --- | --- | --- |
| **Author** | **(*n*), 25-OH(D)** **Mean** **± SD**  **F0-F2** | **(*n*), 25-OH(D) Mean ± SD F3-4** |
| Patel *et al*[32]  2016 | (172)  26.9 ±10.7 | (72)  29.4 ± 15.4 |
| Targher *et al*[26]  2007 | (33)  16.6 ± 10.0 | (6)  6.0 ± 10.8 |
| Anty *et al*[27]  2016 | (381)  19.5 ± 9.1 | (17)  17.7 ± 10.0 |
| Luger *et al*[30]  2016 | (40)  15.2 ± 5.6 | (6)  18.6 ± 6.4 |
| Bril *et al*[29]  2015 | (158)  22.3 ± 13.2 | (27)  24.7 ± 11.5 |
| Barchetta *et al*[28]  2012 | (7)  20.2 ± 11.07 | (18)  26.7 ± 14.2 |

*n*: Number of subjects; 25-OH(D): 25-hydroxylvitamin D; SD: Standard deviation; F0-F4: Severity score of hepatic fibrosis.

**Table 6 Staging systems utilized by hepatologists to assess severity of fibrosis**

|  |  |
| --- | --- |
| **Study** | **Fibrosis stage used** |
| NASH Clinical Research Network Scoring System Definition  Kleiner *et al*[53]*,* 2005 | Seven stages:  F0: No fibrosis  F1a: Mild zone 3 sinusoidal fibrosis  F1b: Moderated zone 3 sinusoidal fibrosis  F1c: Peri-portal sinusoidal fibrosis  F2: Zone 3 sinusoidal fibrosis and peri-portal sinusoidal fibrosis  F3: Bridging fibrosis  F4: Cirrhosis |
| Brunt *et al*[54], 1999 | Stage 1: Zone 3 perisinusoidal/pericellular ﬁbrosis; focally or extensively present  Stage 2: Zone 3 perisinusoidal/pericellular ﬁbrosis with focal or extensive periportal ﬁbrosis  Stage 3: Zone 3 perisinusoidal/pericellular ﬁbrosis and portal ﬁbrosis with focal or extensive bridging ﬁbrosis  Stage 4: Cirrhosis |

NASH: Nonalcoholic steatohepatitis.

**Table 7 Methodology for grading of hepatic fibrosis utilized by the authors of the six included studies**

|  |  |
| --- | --- |
| **Study** | **Fibrosis stage used** |
| Anty *et al*[27], 2016 | Kleiner *et al*[53]*,* 2005 |
| Barchetta *et al*[28], 2012 | Brunt *et al*[54]*,* 1999 |
| Bril *et al*[29], 2015 | Kleiner *et al*[53]*,* 2005 |
| Luger *et al*[30], 2016 | Kleiner *et al*[53]*,* 2005 |
| Patel *et al*[32]*,* 2016 | Kleiner *et al*[53]*,* 2005 |
| Targher *et al*[26]*,* 2007 | Brunt *et al*[54], 1999 |